NAGE (ChromaDex Corp.) יחס שווי שוק לשווי בספרים
This daily price chart for Chromadex Corp (NAGE) represents a company developing advanced medical devices and longevity products based on scientific research. The asset metric is 2.31. The business relies on unique patent control over Niagen and exclusive raw material supplies; however, low barriers to entry in the dietary supplement sector create risks due to a multitude of small players.
%20-%20%D7%99%D7%97%D7%A1%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A9%D7%95%D7%A7%20%D7%9C%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%A0%D7%A7%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_NAGE_-_Chromadex-Corp_-_Market-Cap-to-Net-Assets-Ratio "NAGE יחס שווי שוק לערך בספרים Chromadex Corp (20.03.2025 - 27.10.2026) | 👁️GURU.Markets👁️")
NAGE (niagenbioscience.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים
For Chromadex Corp (NAGE), which seeks dominance in the NAD+ segment via Niagen, the price-to-book ratio history reflects the market's valuation of its intellectual property potential relative to net assets. Sharp spikes in this ratio signal a business revaluation driven by external shocks, allowing investors to distinguish a fair innovation premium from the risks of capital degradation.